FDA approves Jazz Pharma's leukemia drug

The Food and Drug Administration on Aug. 3 approved Jazz Pharmaceuticals' acute myeloid leukemia treatment Vyxeos.

Here are three things to know.

  1. Vyxeos is a fixed-combination therapy containing two chemotherapy drugs.

  1. The drug is intended to treat adults with two types of high-risk AML.

  1. In a recent clinical trial, patients taking Vyxeos had a median overall survival of 9.56 months, compared to 5.95 months for those receiving the two chemotherapy drugs separately.

More articles on supply chain:

Device recalls fall in Q2, drug recalls rise: 10 report findings
Woman sues CVS over generic drug co-pay 'clawbacks'
Fujifilm recalls duodenoscopes over infection risk

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars